Bayer Total Non-Operating Income/Expense 2010-2024 | BAYRY
Bayer annual/quarterly total non-operating income/expense history and growth rate from 2010 to 2024. Total non-operating income/expense can be defined as the sum of all non-operating expenses for the given industry.
- Bayer total non-operating income/expense for the quarter ending September 30, 2024 was $-0.577B, a 24.55% decline year-over-year.
- Bayer total non-operating income/expense for the twelve months ending September 30, 2024 was $-2.371B, a 1.71% decline year-over-year.
- Bayer annual total non-operating income/expense for 2023 was $-2.417B, a 2.06% decline from 2022.
- Bayer annual total non-operating income/expense for 2022 was $-2.468B, a 59.58% increase from 2021.
- Bayer annual total non-operating income/expense for 2021 was $-1.546B, a 25.23% increase from 2020.
Bayer Annual Total Non-Operating Income/Expense
(Millions of US $) |
| 2023 |
$-2,417 |
| 2022 |
$-2,468 |
| 2021 |
$-1,546 |
| 2020 |
$-1,235 |
| 2019 |
$-1,466 |
| 2018 |
$-1,885 |
| 2017 |
$-1,499 |
| 2016 |
$-1,278 |
| 2015 |
$-1,116 |
| 2014 |
$-1,304 |
| 2013 |
$-966 |
| 2012 |
$-916 |
| 2011 |
$102 |
| 2010 |
$-392 |
| 2009 |
$-298 |
Bayer Quarterly Total Non-Operating Income/Expense
(Millions of US $) |
| 2024-09-30 |
$-577 |
| 2024-06-30 |
$-666 |
| 2024-03-31 |
$-544 |
| 2023-12-31 |
$-584 |
| 2023-09-30 |
$-765 |
| 2023-06-30 |
$-674 |
| 2023-03-31 |
$-394 |
| 2022-12-31 |
$-579 |
| 2022-09-30 |
$-602 |
| 2022-06-30 |
$-736 |
| 2022-03-31 |
$-550 |
| 2021-12-31 |
$-611 |
| 2021-09-30 |
$-396 |
| 2021-06-30 |
$-119 |
| 2021-03-31 |
$-420 |
| 2020-12-31 |
$-199 |
| 2020-09-30 |
$-13 |
| 2020-06-30 |
$-304 |
| 2020-03-31 |
$-719 |
| 2019-12-31 |
$-372 |
| 2019-09-30 |
$-199 |
| 2019-06-30 |
$-536 |
| 2019-03-31 |
$-359 |
| 2018-12-31 |
$-872 |
| 2018-09-30 |
$-788 |
| 2018-06-30 |
$-384 |
| 2018-03-31 |
$160 |
| 2017-12-31 |
$-244 |
| 2017-09-30 |
$-474 |
| 2017-06-30 |
$-445 |
| 2017-03-31 |
$-336 |
| 2016-12-31 |
$-270 |
| 2016-09-30 |
$-306 |
| 2016-06-30 |
$-355 |
| 2016-03-31 |
$-348 |
| 2015-12-31 |
$-178 |
| 2015-09-30 |
$-312 |
| 2015-06-30 |
$-317 |
| 2015-03-31 |
$-309 |
| 2014-12-31 |
$-448 |
| 2014-09-30 |
$-401 |
| 2014-06-30 |
$-237 |
| 2014-03-31 |
$-218 |
| 2013-12-31 |
$-119 |
| 2013-09-30 |
$-302 |
| 2013-06-30 |
$-294 |
| 2013-03-31 |
$-251 |
| 2012-12-31 |
$-209 |
| 2012-09-30 |
$-215 |
| 2012-06-30 |
$-260 |
| 2012-03-31 |
$-232 |
| 2011-12-31 |
$152 |
| 2011-09-30 |
$-187 |
| 2011-06-30 |
$79 |
| 2011-03-31 |
$57 |
| 2010-12-31 |
$61 |
| 2010-09-30 |
$-48 |
| 2010-06-30 |
$-114 |
| 2010-03-31 |
$-291 |
| 2009-12-31 |
$-72 |
| 2009-09-30 |
$-129 |
| 2009-06-30 |
$163 |
| 2009-03-31 |
$-262 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$22.242B |
$51.553B |
|
Bayer AG is a life science company with core competencies in the areas of health care and agriculture. With the company's focus completely on the Life Science businesses, a new organizational structure was introduced effective Jan 1, 2016. Bayer Group now comprise exclusively of the Life Science businesses. The company started reporting in three segments ' Pharmaceuticals, Consumer Health and Crop Science ' from the third quarter of 2019. Both Animal Health and Currenta were reported as discontinued operations in the quarter. The company acquired U.S. seed giant Monsanto in June, 2018. With the acquisition, Bayer now has the strongest portfolio of seed and crop protection products for a wide range of crops and indications, the best research and development platform and the leading digital farming business.
|
